当前位置: X-MOL 学术JAMA Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
JAMA Neurology ( IF 20.4 ) Pub Date : 2023-02-06 , DOI: 10.1001/jamaneurol.2022.5272
Niklas Mattsson-Carlgren 1, 2, 3 , Gemma Salvadó 1 , Nicholas J Ashton 4, 5, 6, 7 , Pontus Tideman 1, 8 , Erik Stomrud 1, 8 , Henrik Zetterberg 4, 9, 10, 11, 12 , Rik Ossenkoppele 1, 13, 14 , Tobey J Betthauser 15, 16 , Karly Alex Cody 15, 16 , Erin M Jonaitis 15, 16 , Rebecca Langhough 15, 16 , Sebastian Palmqvist 1, 8 , Kaj Blennow 4, 9 , Shorena Janelidze 1 , Sterling C Johnson 15, 16 , Oskar Hansson 1, 8
Affiliation  

Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid (Aβ) accumulation without symptoms. The duration of this phase differs greatly among individuals. While this disease phase has high relevance for clinical trial designs, it is currently unclear how to best predict the onset of clinical progression.

中文翻译:

使用血浆生物标志物预测临床前阿尔茨海默病的纵向认知衰退。

阿尔茨海默病 (AD) 的病理学始于 β-淀粉样蛋白 (Aβ) 长期积累但无症状。这个阶段的持续时间因人而异。虽然该疾病阶段与临床试验设计具有高度相关性,但目前尚不清楚如何最好地预测临床进展的发生。
更新日期:2023-02-06
down
wechat
bug